NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY

INTRODUCTION: Severe Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurs in ~ 30% of Diffuse Large B Cell Lymphoma (DLBCL) patients treated with CAR-T cell therapy. The current treatment for severe ICANS is glucocorticoids, and this may be combined with tocilizumab for concurrent c...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Neuro Oncol
मुख्य लेखकों: Mokhtari, Sepideh, Asquith, Justin, Bachmeier, Christina, Faramand, Rawan, Kim, Youngchul, Peguero, Edwin, Sahebjam, Solmaz, Jain, Michael, Vogelbaum, Michael, Davila, Marco, Forsyth, Peter, Locke, Frederick, Aleksandr, Lazaryan
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2020
विषय:
Neurological Complications of Cancer
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651408/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.538
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन